Incyte (INCY) Misses Q4 EPS by 76c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Incyte (INCY) Misses Q4 EPS by 76c

Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

February 8, 2022 7:00 AM EST

Total product and royalty revenues of $813 million (+20%) in Q421 and $2.891 billion (+17%) in FY21 Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q421 and $2.135 billion (+10%) in FY21; Jakafi guidance range of $2.3 to $2.4 billion for 2022 Successful U.S. launch of Opzelura (ruxolitinib) cream in atopic dermatitis with nearly 19,000 patients treated from launch (October 11th) through the end of the year Vitiligo is the next substantial growth opportunity for ruxolitinib cream under Priority Review in the U.S. and under review in Europe

Conference Call and Webcast Scheduled Today at 8:00 a.m.... More